288 related articles for article (PubMed ID: 19552489)
1. Current treatment of pseudomonal infections in the elderly.
Pappas G; Saplaoura K; Falagas ME
Drugs Aging; 2009; 26(5):363-79. PubMed ID: 19552489
[TBL] [Abstract][Full Text] [Related]
2. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.
Rossolini GM; Mantengoli E
Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():17-32. PubMed ID: 15953020
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
4. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections.
Driscoll JA; Brody SL; Kollef MH
Drugs; 2007; 67(3):351-68. PubMed ID: 17335295
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum.
Traugott KA; Echevarria K; Maxwell P; Green K; Lewis JS
Pharmacotherapy; 2011 Jun; 31(6):598-608. PubMed ID: 21923444
[TBL] [Abstract][Full Text] [Related]
6. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician.
Martis N; Leroy S; Blanc V
J Infect; 2014 Jul; 69(1):1-12. PubMed ID: 24631777
[TBL] [Abstract][Full Text] [Related]
7. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
Banerjee D; Stableforth D
Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
[TBL] [Abstract][Full Text] [Related]
8. Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains.
Tumbarello M; Raffaelli F; Peghin M; Losito AR; Chirico L; Giuliano G; Spanu T; Sartor A; Fiori B; Bassetti M
Int J Antimicrob Agents; 2020 Apr; 55(4):105900. PubMed ID: 31931150
[TBL] [Abstract][Full Text] [Related]
9. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update.
Reynolds D; Kollef M
Drugs; 2021 Dec; 81(18):2117-2131. PubMed ID: 34743315
[TBL] [Abstract][Full Text] [Related]
10. Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy.
Lynch JP; Zhanel GG; Clark NM
Semin Respir Crit Care Med; 2017 Jun; 38(3):326-345. PubMed ID: 28578556
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.
Mesaros N; Nordmann P; Plésiat P; Roussel-Delvallez M; Van Eldere J; Glupczynski Y; Van Laethem Y; Jacobs F; Lebecque P; Malfroot A; Tulkens PM; Van Bambeke F
Clin Microbiol Infect; 2007 Jun; 13(6):560-78. PubMed ID: 17266725
[TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
13. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
Borgatta B; Gattarello S; Mazo CA; Imbiscuso AT; Larrosa MN; Lujàn M; Rello J
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2155-2163. PubMed ID: 28624864
[TBL] [Abstract][Full Text] [Related]
15. Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors.
Trinh TD; Zasowski EJ; Claeys KC; Lagnf AM; Kidambi S; Davis SL; Rybak MJ
Diagn Microbiol Infect Dis; 2017 Sep; 89(1):61-66. PubMed ID: 28716451
[TBL] [Abstract][Full Text] [Related]
16. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation.
Nesher L; Rolston KV; Shah DP; Tarrand JT; Mulanovich V; Ariza-Heredia EJ; Chemaly RF
Transpl Infect Dis; 2015 Feb; 17(1):33-8. PubMed ID: 25546740
[TBL] [Abstract][Full Text] [Related]
17. Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'.
Araoka H; Baba M; Takagi S; Matsuno N; Ishiwata K; Nakano N; Tsuji M; Yamamoto H; Seo S; Asano-Mori Y; Uchida N; Masuoka K; Wake A; Taniguchi S; Yoneyama A
Scand J Infect Dis; 2010 Mar; 42(3):231-3. PubMed ID: 20001223
[TBL] [Abstract][Full Text] [Related]
18. Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.
Elphick HE; Scott A
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD002007. PubMed ID: 27907224
[TBL] [Abstract][Full Text] [Related]
19. A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.
Pritchard MF; Powell LC; Jack AA; Powell K; Beck K; Florance H; Forton J; Rye PD; Dessen A; Hill KE; Thomas DW
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630204
[TBL] [Abstract][Full Text] [Related]
20. Multidrug-resistant Gram-negative infections: what are the treatment options?
Giamarellou H; Poulakou G
Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
